Investors have pumped $60 million into Gilgamesh Pharma to test a handful of psychedelics and other experimental neuroscience medicines that the biotech hasn’t yet promised

MSD’s glut of pipeline-boosting deals in the build-up to a looming patent cliff is reported to be continuing with a $6bn bid to acquire Terns

Ocugen said it will take its gene therapy for a form of vision loss into a Phase 3 trial, after reporting mixed results on Tuesday

The FDA warned California-based ImmunityBio for a TV advertisement and podcast that gave the “misleading impression” that Anktiva, the company’s treatment for a type of

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.